Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
Locations
1
Canada
Hospital Maissoneuve
Montreal, Quebec, Canada
Start Date
March 1, 2016
Primary Completion Date
January 1, 2020
Completion Date
January 1, 2020
Last Updated
August 14, 2019
Lead Sponsor
daphne brockington
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions